STOCK TITAN

Adia Med (ADIA) SEC Filings, Dec 5, 2025

ADIA OTC
Rhea-AI Summary

Adia Nutrition, Inc. files a Form 10 to register its Common A Stock under the Exchange Act and describe its transition from a dormant shell into an operating regenerative medicine and supplements business. After court-appointed custodianship and several control changes, the company now runs Adia Med clinics and Adia Labs, focusing on autologous stem cell procedures and umbilical cord stem cell biologics such as AdiaVita and AdiaLink, alongside an 18% stake in supplement seller Cement Factory.

Revenue grew to $637,145 for the nine months ended September 30, 2025, mainly from biologic product sales and medical procedures, but the company still recorded a net loss and has an accumulated deficit over $15 million, leading auditors to raise substantial doubt about its ability to continue as a going concern. Operations depend heavily on a related-party credit line, a third‑party lab, and navigating complex FDA and AATB rules for human tissue products. The filing also highlights significant regulatory, competitive, liquidity and penny‑stock risks, as well as concentrated voting control through a single preferred share class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.43%
Tags
other

FAQ

How many Adia Med (ADIA) SEC filings are available on StockTitan?

StockTitan tracks 11 SEC filings for Adia Med (ADIA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Adia Med (ADIA)?

The most recent SEC filing for Adia Med (ADIA) was filed on November 16, 2026.